The obstacles to entry into the marketplace allow 3 companies to play 3 card Monte with patterns on the latest irritation of insulin. Couple that with the insulation of the consumer from the actual price of the product (through health insurance) and u have an environment where drugs like insulin (that don't naturally lend themselves to cheaper generic versions) increase in cost over time.

It's funny how in mixed economies you have regulatory policy that insulates companies from competative pressure and somehow it's the market side that is declared deficient.

---